Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Odevixibat
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Health Canada Approves Bylvay for the Treatment of Cholestatic Pruritus
Details : Bylvay (odevixibat) is an Ileal bile acid transporter inhibitor indicated for the treatment of cholestatic pruritus in patients with alagille syndrome.
Product Name : Bylvay
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 09, 2025
Lead Product(s) : Odevixibat
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Patisiran
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Alnylam Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Medison and Alnylam Expand RNAi Therapeutics Partnership in Europe, Israel, and LATAM/APAC
Details : Alnylam's collaboration with Medison leverages Medison’s multi-regional platform to make RNAi therapeutics like ONPATTRO, GIVLAARI, and OXLUMO available in LATAM, APAC, and additional global markets.
Product Name : Onpattro
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
April 30, 2024
Lead Product(s) : Patisiran
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Alnylam Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Cemiplimab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Medison Pharma Partners with Regeneron to Commercialize Libtayo® Globally
Details : Medison will commercialize Libtayo (cemiplimab), an anti-PD-1 monoclonal antibody, in select European and global markets under a new agreement.
Product Name : Libtayo
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
January 08, 2024
Lead Product(s) : Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Givosiran Sodium
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Alnylam Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : The new agreement will allow Alnylam to utilize Medison's unique multi-regional platform to ensure that Alnylam's innovative RNAi therapeutics, such as ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran) are made available across additiona...
Product Name : Givlaari
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
March 09, 2023
Lead Product(s) : Givosiran Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Alnylam Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : Tebentafusp
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Immunocore
Deal Size : Undisclosed
Deal Type : Agreement
Details : Kimmtrak (tebentafusp) is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. Tebentafusp specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma.
Product Name : Kimmtrak
Product Type : Protein
Upfront Cash : Undisclosed
November 09, 2022
Lead Product(s) : Tebentafusp
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Immunocore
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Imlifidase
Therapeutic Area : Immunology
Study Phase : Approved FDF
Recipient : Hansa Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Idefirix® (imlifidase) becomes the first and only product reimbursed for the desensitization of highly sensitized patients waiting for a kidney transplant in Poland.
Product Name : Idefirix
Product Type : Enzyme
Upfront Cash : Inapplicable
August 22, 2022
Lead Product(s) : Imlifidase
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Hansa Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Odevixibat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Approved FDF
Sponsor : Albireo Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the agreement with Albireo, Medison aims to commercialize Odevixibat in Canada and Israel, for the treatment of patients with cholestatic liver diseases. Odevixibat is approved in Europe as Bylvay® for the treatment of progressive familial intrahe...
Product Name : Bylvay
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 16, 2022
Lead Product(s) : Odevixibat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved FDF
Sponsor : Albireo Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Efgartigimod Alpha
Therapeutic Area : Immunology
Study Phase : Approved FDF
Recipient : Argenx
Deal Size : Undisclosed
Deal Type : Partnership
Details : Efgartigimod is approved in the United States as VYVGART® for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and in Japan for the treatment of adults with gMG.
Product Name : Vyvgart
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
June 06, 2022
Lead Product(s) : Efgartigimod Alpha
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Argenx
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Tebentafusp
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Immunocore
Deal Size : Undisclosed
Deal Type : Agreement
Details : The multi-territorial agreement to help seek regulatory authorization and commercialize Immunocore's KIMMTRAK® (tebentafusp -tebn) for the treatment of unresectable or metastatic uveal melanoma, a rare and aggressive form of melanoma that affects the ey...
Product Name : Kimmtrak
Product Type : Protein
Upfront Cash : Undisclosed
May 23, 2022
Lead Product(s) : Tebentafusp
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Immunocore
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Zanubrutinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : BeOne Medicines
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BRUKINSA is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) discovered by BeiGene scientists that is currently being evaluated globally in a broad clinical program as a monotherapy and in combination with other therapies to treat various B...
Product Name : Brukinsa
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 15, 2022
Lead Product(s) : Zanubrutinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : BeOne Medicines
Deal Size : Inapplicable
Deal Type : Inapplicable